Cartesian Therapeutics Inc (NAS:RNAC)
$ 36.1 0.1 (0.28%) Market Cap: 642.44 Mil Enterprise Value: 537.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Selecta Biosciences Inc Reports DISSOLVE Phase 3 Clinical Trials in Chronic Refractory Gout Transcript

Mar 21, 2023 / 12:30PM GMT
Release Date Price: $37.8 (-1.56%)
Operator

Good morning, and welcome to the Selecta conference call on the top line results from DISSOLVE I and II, the Phase III trials of SEL-212 in chronic refractory gout. (Operator Instructions) As a reminder, this conference is being recorded.

For opening remarks, I would like to introduce Blaine Davis, Chief Financial Officer of Selecta. Please go ahead, sir.

Blaine T. Davis
Selecta Biosciences, Inc. - CFO

Thanks, operator. Good morning, and welcome to today's call, where we will share with you the exciting top line results from DISSOLVE I and II, the Phase III trials of SEL-212 in chronic refractory gout. The press release announced in these top line results is available in the Investors section of Selecta's website at www.selectabio.com, and today's presentation has been posted there for your review.

Joining me on today's call are Carsten Brunn, President, and Chief Executive Officer; Peter Traber, our Chief Medical Officer; and Kei Kishimoto, Chief Scientific Officer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot